For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...
A new study identified key factors that can impact the long-term weight loss of patients with obesity who were prescribed injectable semaglutide or liraglutide for the treatment of type 2 diabetes or ...
A new study finds that weight loss drugs Like Ozempic could trigger bone loss. Doctors explain why, and how to protect ...
A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were ...
The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...
Some people lose more weight on drugs like Ozempic, Wegovy and Saxenda than others, and a new study reveals why that might be.
Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...
UNSW medical researchers say more Australians with type 2 diabetes need to be offered add-on medications that would better ...
Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide (Ozempic, ...
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...
About Veru Inc. Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The Company’s drug ...
A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were ...